Abpro and NJCTTQ Enter Into Partnership for Development of Multiple Novel Bispecific Antibodies Abpro eligible to receive up to $4 billion, including $60 million in near-term R&D funding, plus potential milestones and royaltiesCollaboration to result in multiple new immuno-oncology...